IL123232A0 - Medicament for inhibiting glucose metabolism deterioration - Google Patents

Medicament for inhibiting glucose metabolism deterioration

Info

Publication number
IL123232A0
IL123232A0 IL12323298A IL12323298A IL123232A0 IL 123232 A0 IL123232 A0 IL 123232A0 IL 12323298 A IL12323298 A IL 12323298A IL 12323298 A IL12323298 A IL 12323298A IL 123232 A0 IL123232 A0 IL 123232A0
Authority
IL
Israel
Prior art keywords
medicament
glucose metabolism
inhibiting glucose
deterioration
metabolism deterioration
Prior art date
Application number
IL12323298A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL123232A0 publication Critical patent/IL123232A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL12323298A 1997-02-11 1998-02-09 Medicament for inhibiting glucose metabolism deterioration IL123232A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79866197A 1997-02-11 1997-02-11

Publications (1)

Publication Number Publication Date
IL123232A0 true IL123232A0 (en) 1999-11-30

Family

ID=25173964

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12323298A IL123232A0 (en) 1997-02-11 1998-02-09 Medicament for inhibiting glucose metabolism deterioration

Country Status (12)

Country Link
EP (1) EP0857483A1 (no)
JP (1) JPH10218773A (no)
KR (1) KR19980071226A (no)
AU (1) AU5387898A (no)
CA (1) CA2229123A1 (no)
CZ (1) CZ39398A3 (no)
HU (1) HUP9800291A2 (no)
IL (1) IL123232A0 (no)
MX (1) MX9801129A (no)
NO (1) NO980546L (no)
SG (1) SG76535A1 (no)
ZA (1) ZA981029B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044355A1 (en) * 1999-01-29 2000-08-03 Eli Lilly And Company Moxonidine salts
ITTV20010002U1 (it) 2001-01-12 2002-07-12 Vetraria Biancadese Sas Soc Tavolo avente almeno una prolunga estraibile mediante semplice rotazione
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
PL378295A1 (pl) * 2003-02-24 2006-03-20 Arena Pharmaceuticals, Inc. Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004283047B2 (en) * 2003-10-10 2009-09-17 Abbott Laboratories Gmbh Pharmaceutical composition comprising a selective I1 imidazoline receptor agonist and an angiotensin II receptor blocker
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
KR20080090546A (ko) * 2006-01-27 2008-10-08 에프. 호프만-라 로슈 아게 Ｃｎｓ 장애 치료용 2-이미다졸의 용도
ATE546437T1 (de) 2006-10-19 2012-03-15 Hoffmann La Roche Aminomethyl-4-imidazole
EP2086959B1 (en) 2006-11-02 2011-11-16 F. Hoffmann-La Roche AG Substituted 2-imidazoles as modulators of the trace amine associated receptors
JP2010510184A (ja) 2006-11-16 2010-04-02 エフ．ホフマン−ラ ロシュ アーゲー 置換４−イミダゾール類
AU2007332641A1 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (TAAR)
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
RU2473545C2 (ru) 2007-02-02 2013-01-27 Ф.Хоффманн-Ля Рош Аг Новые 2-аминооксазолины в качестве лигандов taar1 для заболеваний цнс
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
WO2009003868A2 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (taars)
AU2008270444A1 (en) 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
EP2183216A1 (en) 2007-07-27 2010-05-12 F. Hoffmann-Roche AG 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
CN101784515A (zh) 2007-08-03 2010-07-21 弗·哈夫曼-拉罗切有限公司 作为taar1配体的吡啶甲酰胺和苯甲酰胺衍生物
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
EP2829540A1 (en) 2013-07-26 2015-01-28 Abbott Healthcare Products B.V. Synthesis of substituted aminopyridines
CN116850181A (zh) 2015-01-06 2023-10-10 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
MX2017016530A (es) 2015-06-22 2018-03-12 Arena Pharm Inc Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1).
CR20180443A (es) 2016-03-17 2018-11-21 Hoffmann La Roche Derivado de morfolina

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel

Also Published As

Publication number Publication date
MX9801129A (es) 1998-11-29
CA2229123A1 (en) 1998-08-11
EP0857483A1 (en) 1998-08-12
NO980546L (no) 1998-08-12
HU9800291D0 (en) 1998-04-28
SG76535A1 (en) 2000-11-21
CZ39398A3 (cs) 1998-08-12
ZA981029B (en) 1999-08-10
AU5387898A (en) 1998-08-13
NO980546D0 (no) 1998-02-09
HUP9800291A2 (hu) 2001-02-28
KR19980071226A (ko) 1998-10-26
JPH10218773A (ja) 1998-08-18

Similar Documents

Publication Publication Date Title
IL123232A0 (en) Medicament for inhibiting glucose metabolism deterioration
IL130027A0 (en) Sulfonylurea- glitazone synergistic combinations for diabetes
ZA989744B (en) Method for administering acylated insulin.
EP1010432A4 (en) REMEDIES FOR DIABETES
GB9817118D0 (en) Pharmaceutical compounds
IL137105A0 (en) Method for administering aspb28-human insulin
GB9700504D0 (en) Pharmaceutical compounds
GB9810886D0 (en) Pharmaceutical compounds
EP1003495A4 (en) PHARMACEUTICAL COMPOUNDS
GB9716244D0 (en) Pharmaceutical compounds
GB2343440B (en) Medicine packs
GB9800750D0 (en) Pharmaceutical compound
IL122920A (en) Castrointestinal drug composition
IL126671A0 (en) Drug preferably for inhibiting inflammation
GB9700895D0 (en) Pharmaceutical compounds
GB9827865D0 (en) Medicament
GB0005108D0 (en) Glucose responsive -cell line
GB2329335B (en) Medicament
GB0002424D0 (en) Medicament
GB9702946D0 (en) Medicament
GB9726234D0 (en) Medicament
HUP9903097A3 (en) Medicament containing progestogen-anti-progestogen
GB9827285D0 (en) Medicament
GB9725661D0 (en) Ptient-prompted medication
GB9714631D0 (en) Pharmaceutical compound